Dizal Pharmaceutical (688192.SH) receives USD 600 million upfront payment from AstraZeneca for the global licensing of Sunvozertinib

Dizal Pharmaceutical (688192.SH) has announced that it recently received a USD 600 million upfront payment from AstraZeneca. The arrival of this payment has effectively strengthened the company's cash reserves, providing strong support for the company's continued advancement of global development and commercialization for its innovative pipeline. This receipt is expected to have a positive impact on the company's 2026 performance and financial condition, with the specific amount subject to audited data. Under the terms of the agreement, the company has granted AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib. In addition to the upfront payment, the company will also receive milestone payments of up to USD 900 million tied to specific clinical development, regulatory approvals, and sales achievements, as well as tiered royalties on global sales.